Author: lymphomaprogram

Located on the Upper East Side of New York City, the Lymphoma Program at Weill Cornell Medical College/NewYork Presbyterian Hospital is internationally recognized for our efforts to enable patients with non-Hodgkin lymphoma, Hodgkin disease and related disorders to have the best possible clinical outcome, including cure when possible.

LLS Patient Education: Novel Therapeutic Options for Lymphoma, An Evening with Experts from Weill Cornell

Novel Therapeutic Options for Lymphoma:
What Every Patient Needs to Know about Ibrutinib, Idelalisib, and Other New Drug

The Leukemia & Lymphoma Society (LLS) in partnership with Weill Cornell Medical College and NewYork-Presbyterian Weill Cornell Medical Center are presenting a patient education event on Wednesday, April 30 at Weill Cornell Medical College.

Click here to register or contact Trisha Ouellette at (212) 376-4762.

Topics:

  • General overview of lymphoma
  • Clinical Trials/Select New Therapies
  • Complementary Medicine
  • Panel Discussion/Q&A

Moderators:

John Leonard, MD

Speakers:

Richard Furman, MD
Peter Martin, MD
Jia Ruan, MD

Date and Time:

Wednesday, April 30, 2014 5:30pm-8pm

Location:

The Griffis Faculty Club at Weill Cornell Medical College
521 East 68th Street (east of York Avenue)
New York, NY 10021

A light dinner will be provided

More information can be found here. 

Palbociclib Displays Promising Results

Palbociclib (PD 0332991) is generating significant excitement according to an April 6th online article from the New York Times. The article cites the results of a recently reported phase II trial in which women with metastatic breast cancer were randomized to receive letrozole plus palbociclib or letrozole alone. Women receiving the combination had their risk of progression cut in half compared to the group that received letrozole alone. These results come roughly one year after the FDA granted Breakthrough Therapy designation to palbociclib, which may help speed up the drug approval process.

Palbociclib is a highly specific oral drug that binds to and inhibits a specific subtype of enzymes called cyclin-dependent kinases (CDK). The same enzymes are critical to the development and progression of mantle cell lymphoma (MCL). Investigators at Weill Cornell Medical College have been leading the evaluation of palbociclib in MCL. Within the next month, we will open a phase I trial evaluating the combination of palbociclib plus ibrutinib in patients with previously treated MCL. For additional information regarding the upcoming trial or other trials in lymphoma, call Amelyn Rodriguez, RN at (212) 746-1362 or e-mail Amelyn at amr2017@med.cornell.edu.

Dr. Ari Melnick Discusses the Challenges of Measuring Tumor Heterogeneity

Earlier this week Dr. Ari Melnick answered another question from Targeted Oncology concerning the challenges associated with measuring tumor heterogeneity in finding new avenues for targeted therapy.